Currently, there are 129.54M common shares owned by the public and among those 94.29M shares have been available to trade.
The company’s stock has a 5-day price change of 612.49% and 679.40% over the past three months. PROK shares are trading 81.60% year to date (YTD), with the 12-month market performance up to 168.64% higher. It has a 12-month low price of $0.46 and touched a high of $7.13 over the same period. PROK has an average intraday trading volume of 11.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 211.83%, 329.18%, and 224.98% respectively.
Institutional ownership of ProKidney Corp (NASDAQ: PROK) shares accounts for 41.58% of the company’s 129.54M shares outstanding.
It has a market capitalization of $1.33B and a beta (3y monthly) value of 1.61. The earnings-per-share (ttm) stands at -$0.60. Price movements for the stock have been influenced by the stock’s volatility, which stands at 103.33% over the week and 38.80% over the month.
Earnings per share for the fiscal year are expected to increase by 21.23%, and -4.25% over the next financial year.
Looking at the support for the PROK, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on June 30, 2025, with the firm’s price target at $1. Guggenheim was of a view on September 10, 2024 that the stock is Buy, while Morgan Stanley gave the stock Equal-Weight rating on March 07, 2024, issuing a price target of $3. BofA Securities on their part issued Neutral rating on January 02, 2024.
